Quentin Jacquinot

CHU Minjoz, Bâtiment Bleu, Niveau 0, Boulevard Fleming
Besancon, 25030, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté

ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté

Journal: Bulletin du cancer

Published: October 31, 2025

Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy.

Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy.

Journal: Breast cancer research and treatment

Published: October 28, 2025

Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study.

Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study.

Journal: Breast cancer research and treatment

Published: July 29, 2025

Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibility.

Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibility.

Journal: BMJ supportive & palliative care

Published: July 01, 2024

Exercise Intervention on Insomnia in Patients with a Cancer: A Systematic Review of the Literature.

Exercise Intervention on Insomnia in Patients with a Cancer: A Systematic Review of the Literature.

Journal: Cancers

Published: April 30, 2024

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.

Journal: BMC cancer

Published: April 11, 2023

Physical activity in the oncology care pathway: Expectations and perspectives

Physical activity in the oncology care pathway: Expectations and perspectives

Journal: Bulletin du cancer

Published: November 02, 2022

There is a need for a complete consideration of overall movement behaviors for the prevention, treatment, and follow-up of cancer risks and patients.

There is a need for a complete consideration of overall movement behaviors for the prevention, treatment, and follow-up of cancer risks and patients.

Journal: Frontiers in public health

Published: October 26, 2022

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Journal: Frontiers in cardiovascular medicine

Published: July 22, 2022

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.

Journal: Frontiers in oncology

Published: March 20, 2021

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Journal: Breast (Edinburgh, Scotland)

Published: March 03, 2018

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Journal: BMC cancer

Published: March 14, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026